Last reviewed · How we verify
tamsolusin
At a glance
| Generic name | tamsolusin |
|---|---|
| Also known as | Flomax, Harnal |
| Sponsor | Tabriz University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH (PHASE4)
- Effect of Tamsulosin vs Prazosin in Treatment of Female Voiding Dysfunction (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tamsolusin CI brief — competitive landscape report
- tamsolusin updates RSS · CI watch RSS
- Tabriz University portfolio CI